S
S D Robb
Researcher at Western Infirmary
Publications - 12
Citations - 886
S D Robb is an academic researcher from Western Infirmary. The author has contributed to research in topics: Heart failure & Heart disease. The author has an hindex of 7, co-authored 12 publications receiving 812 citations.
Papers
More filters
Journal ArticleDOI
N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure.
TL;DR: A single measurement of NT-proBNP in patients with advanced CHF, can help to identify patients at highest risk of death, and is a better prognostic marker than the LVEF, VO2or HFSS.
Journal ArticleDOI
The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study.
A. Zaphiriou,S D Robb,Tarita Murray-Thomas,Gustavo F Mendez,Kevin Fox,Theresa McDonagh,Suzanna M C Hardman,Henry J. Dargie,Martin R. Cowie +8 more
TL;DR: To determine the diagnostic accuracy of the measurement of plasma B‐type natriuretic peptide (BNP) and N‐terminal pro‐BNP (NTproBNp) in patients referred by their general practitioners with symptoms suggestive of heart failure, a comparison of the resting 12‐lead electrocardiogram (ECG) with that of the peptides is compared.
Journal ArticleDOI
Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979–1992
David R. Murdoch,M.P. Love,S D Robb,Theresa A. McDonagh,Andrew Davie,Ian Ford,Simon Capewell,Caroline Morrison,Jjv McMurray +8 more
TL;DR: This study is the first to show that standardized mortality rates are declining, and one third or more of deaths currently attributed to coronary heart disease may be related to heart failure and this proportion appears to be increasing.
Journal ArticleDOI
The prevalence of haemochromatosis gene mutations in the West of Scotland and their relation to ischaemic heart disease
TL;DR: The C282Y homozygote and heterozygote prevalences are among the highest reported worldwide, however, these results need to be interpreted in the light of the cross sectional case–control nature of the study.
Journal ArticleDOI
Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial.
Barbara E. Stähli,Jean-Claude Tardif,Michel Carrier,Richard L. Gallo,Robert W. Emery,S D Robb,Daniel Cournoyer,Lucie Blondeau,Dominique Johnson,Jessica M. Mann,Jacques Lespérance,Marie-Claude Guertin,Philippe L. L’Allier +12 more
TL;DR: Despite unprecedented advances over the last few decades, saphenous vein graft failure remains a major concern following coronary artery bypass graft (CABG) surgery, and since contemporary treatment options are limited in these patients, there is an unmet need for novel therapeutic options.